The CNS disease drug developer has raised funding in a GV-backed round just four months after it emerged from stealth with $30m.
US-based gene therapy developer Taysha Gene Therapies completed a $95m series B round on Wednesday backed by GV, a corporate venture capital subsidiary of internet and technology group Alphabet.
Investment and financial services group Fidelity Management & Research led the round, which included Invus, Casdin Capital, Franklin Templeton, Octagon Capital and Perceptive Advisors.
The round was filled out by Sands Capital, ArrowMark Partners,Venrock Healthcare Capital Partners, PBM Capital, Nolan Capital and funds and accounts managed by BlackRock.
Taysha is working…
